MastCURe, a high-profile research consortium, has been awarded EUR1.3M in funding from the Eureka Eurostars program. The collaboration comprising Allegria Therapeutics, Cube Biotech, and the ...
Septerna plans to advance SEP-631 into Phase 2 development in CSU and chronic inducible urticaria and is evaluating its potential in additional mast cell-driven indications, including atopic ...
Enanta Pharma begins dosing in phase 1 trial of EDP-978, an oral, once-daily KIT inhibitor, in development to treat urticaria: Watertown, Massachusetts Tuesday, April 14, 2026, 15 ...
According to an international multicenter study, CD2-negative mast cells are associated with significantly reduced overall survival in patients with SM. Patients with CD2-negative mast cells have ...
Food allergies affect more than half a billion people worldwide. In severe cases, even a small bite of the wrong food can trigger anaphylaxis - a rapid, body-wide allergic reaction that can cause ...
Cutaneous mastocytosis is one of two types of mastocytosis, a rare disorder in which too many mast cells — a type of white blood cell that helps the immune system function properly — accumulate in the ...
MastCURe, a high-profile research consortium, has been awarded €1.3M in funding from the Eureka Eurostars program. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results